Thrombocytopenia Management Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Thrombocytopenia Management Market is segmented By Disease type (Idiopathic Thrombocytopenic, Thrombotic Thrombocytopenic, Drug-induced Thrombocytopenia), By End-user (Hospitals, Specialty Clinics, Ambulatory surgical centers), By Region (North America ,South America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Market Overview

The Global "Thrombocytopenia Management Market" is predicted to reach at a high CAGR during the forecast period (2023-2030). 180 pages report analyses the Thrombocytopenia Management market shares, recent trends, growth and forecast. Thrombocytopenia Management Demand from pharmaceuticals & commercial infrastructure in ‘North America ’ is booming. Competitive rivalry intensifies with Amgen Inc., Amarillo Biosciences, Baxalta, Bayer and others operating in the market.

It can also be caused by cancer medications, including chemotherapy and drug-induced medicines, and radiation therapies.

Market Summary

For know more Insights - Download Sample

Market Dynamics

Source: DataM Intelligence Analysis (2020)

Increasing prevalence rates for autoimmune hemolytic anemia is boosting the market growth.

Warm autoimmune hemolytic anemia (WAHA) is characterized by the early destruction of healthy red blood cells (hemolysis). It occurs when one's immune system attacks healthy tissue. In WAHA and other types of autoimmune hemolytic anemia, red blood cells are tagged by antibodies and destroyed by different immune cells. It is the most common type of autoimmune hemolytic anemia.

According to the National Organization for Rare Disorders, WAHA affects approximately 1 to 3 per 100,000 people every year and can occur at any age. Usually, the red blood cells have a life span of roughly 120 days before the spleen destroys them. In patients with WAHA, the red blood cells are destroyed prematurely, and the increasing rate of new cells in the bone marrow can no longer pay for their loss. Additionally, the limited number of red blood cells may cause fatigue, weakness, a pale skin color (pallor), dizziness, palpitations, and shortness of breath (dyspnea). The treatment of WAHA includes corticosteroids and rituximab. Therefore, individuals who do not react to the usual treatment might require drugs that suppress the immune system, blood transfusions, or surgical spleen removal (splenectomy).

The high cost of thrombocytopenia medications and treatment is likely to hamper the market growth.

The FDA has approved the anti–von Willebrand factor immunoglobulin fragment caplacizumab indicated explicitly for treating adults with acquired thrombotic thrombocytopenic purpura (aTTP). But, with a list price of $270,000, the cost of the treatment outweighs its benefits.

In addition, treatment costs were calculated using U.S. list prices and facility costs. Researchers estimated treatment of a TTP episode would require four individual rituximab 375 mg/m2 doses, at the expense of $7,724 per dose; treatment with caplacizumab was $270,000 per episode. In addition, other associated costs accounted for in the model included the institution's expenses for the number of TPE sessions ($6,000/TPE session), intensive care unit length of stay ($1,043/day), and total hospital length of stay ($490/day).

COVID-19 Impact Analysis

COVID-19 pandemic has moderately impacted the healthcare industry. Patients with COVID-19 pneumonia exhibit coagulation abnormalities, most commonly elevated levels of fibrinogen and D-dimer, often with mild thrombocytopenia and appear to have increased platelet consumption, together with a corresponding increase in platelet production. Disseminated intravascular coagulopathy (DIC) and severe bleeding events are uncommon in COVID-19 patients. Moreover, the pandemic is interrupting the medical supply chain, and many companies will vary to other geographic regions in the future to ensure that products remain available and protect their supply chain. However, the situation is expected to improve gradually in the forecast period.

Segment Analysis

The idiopathic Thrombocytopenic segment is expected to hold the largest market share in this market segment.

The idiopathic thrombocytopenic segment was held the largest market share in 2020. The segment growth benefits from the increasing prevalence of idiopathic thrombocytopenic purpura. For instance, according to the Mayoclinic,  idiopathic thrombocytopenic purpura is a disorder that can lead to excessive bruising and bleeding. The bleeding results from deficient levels of platelets — the cells that help blood clot. Children may develop ITP after a viral infection and recover fully without treatment. In adults, the disorder is often long-term. For instance, according to the National Organization for Rare Disorders, The incidence of ITP  and is more common over the age of 60 and increases with age. Among adults (age 30-60) diagnosed with chronic ITP, there are 2.6 cases amongst women for every case involving a male.

Moreover, in older adults, about the same number of men and women are diagnosed with ITP. Among children diagnosed with acute ITP, the male to female ratio is almost equal, with 52% male to 48% female. About 40% of all patients diagnosed with one or another form of ITP are children younger than ten years. Therefore, the incidence is most significant among children between 2 and 4 years of age. However, ITP can occur at 3 months to over 100 years.

Source: DataM Intelligence Analysis (2020)

Geographical Analysis

North America region holds the largest market share in the global thrombocytopenia management market.

North America dominated the market in 2020, owing to the rising thrombocytopenia cases, favorable government initiatives and high research funding in the region is expected to boost the market in the forecast period. For instance, according to the Annals of Blood, published on March 2021, Immune thrombocytopenia (ITP) is a rare heterogeneous autoimmune bleeding disorder that makes a lower than usual circulating platelet count caused by impaired platelet production and accelerated platelet destruction.

Patients with ITP face a set of challenges. The multifaceted burden of living with ITP impacts patients and their families' overall health-related quality of life (HRQoL). Moreover, ITP leads to fatigue, challenges with daily activities, reduced physical functioning, anxiety, and depression. Aside from the constant risk for severe bleeding, patients experience physical and emotional consequences living with their disease daily. Additionally, ITP is primarily chronic in adults, with a higher prevalence in women than men. The prevalence of ITP is 20.3 per 100,000 persons in the United States of America (USA). Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements. 

Source: DataM Intelligence Analysis (2020)

Competitive Landscape

The thrombocytopenia management market is highly competitive with the presence of local and global companies. Some of the key players contributing to the market's growth include Amgen Inc., Amarillo Biosciences, Baxalta, Bayer, BioLineRx, Boehringer Ingelheim Bolder Biotechnology, Bristol-Myers Squibb, Cellerant Therapeutics, Eisai and Genosco. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, contributing to the global growth of the thrombocytopenia management market.

Thrombocytopenia Management Market Key Companies to Watch

Amgen Inc.:

Overview:

Amgen Inc. (Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company focused on molecular biology and biochemistry. The company focuses on therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology and inflammation. Moreover, the company has a presence in around 100 countries and regions worldwide. In 2018, the company's most prominent selling product lines were Neulasta, an immunostimulator used to prevent infections in cancer chemotherapy patients and Enbrel, a tumor necrosis factor blocker used to treat rheumatoid arthritis autoimmune diseases.

Product Portfolio:

Amgen Inc. has continuously set new standards for manufacturing products, including Nplate (romiplostim).

Why Purchase the Report?

• Visualize the composition of the thrombocytopenia management market segmentation by disease type, end-user and region, highlighting the key commercial assets and players.
• Identify commercial opportunities in the thrombocytopenia management market by analyzing trends and co-development deals.
• Excel data sheet with thousands of thrombocytopenia management market-level 4/5 segmentation data points.
• PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
• Product mapping in excel for the key product of all major market players

The global thrombocytopenia management market report would provide access to an approx. 50 market data table, 41 figures and 180 pages.

Target Audience

• Service Providers/ Buyers
• Industry Investors/Investment Bankers
• Education & Research Institutes
• Research Professionals
• Emerging Companies
• Manufacturers